A Comparative evaluation of the efficacy and safety of 2% crisaborole versus 0.1% tacrolimus ointment for the topical treatment of mild to moderate atopic dermatitis

·       Atopic dermatitis (AD) has a high prevalence, approaching 25% in children and 10% in adults, depending on the country of residence.Most patients with AD have mild-to-moderate disease amenable to topical therapy.Treatment of patients with mild and even moderate AD is centered on topical therapies, including emollients, topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs), and a topical phosphodiesterase 4 (PDE4) inhibitors. Use of TCIs and TCSs for long-term disease control might be limited because of side effects, such as skin atrophy (TCSs), local tolerance issues (TCIs), and patient/physician’s reluctance stemming from black box warnings (TCIs).Despite a growing understanding of AD pathomechanisms. No novel topical drugs had been approved for AD in more than a decade until the recent approval of crisaborole. Crisaborole ointment 2% is a nonsteroidal PDE4 inhibitor for the treatment of mild-to-moderate AD. In 2 identically designed, 28-day, phase 3 clinical trials in patients 2 years of age or older with mild-to-moderate AD, crisaborole was well tolerated and superior to vehicle in reducing global disease severity and signs and symptoms of AD. The objective of this study was to determine the efficacy of 2% crisaborole ointment vesus 0.1% tacrolimus ointment for treating mild to moderate cases of AD.